FDA granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for adult patients with unresectable or metastatic NSCLC whose tumors have activating HER2 mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.
Haystack Oncology, a Quest Diagnostics company, and Rutgers Cancer Institute are partnering to evaluate the use of Haystack MRD, a circulating tumor DNA minimal residual disease test, to help optimize postoperative therapy decisions in patients with stage 2/3 non-small cell lung cancer.
